Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Australia
/
Pharmaceuticals & Biotech
/
Neuren Pharmaceuticals
NEU
Neuren Pharmaceuticals
US And EU Regulation Will Erode Prospects Yet Offer Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
AU$18.60
5.1% undervalued
intrinsic discount
22 Aug
AU$17.66
Loading
1Y
13.3%
7D
3.5%
Author's Valuation
AU$18.6
5.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
AU$18.6
5.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-14m
217m
2014
2017
2020
2023
2025
2026
2028
Revenue AU$94.7m
Earnings AU$13.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-6.25%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.48%
Calculation
AU$13.84m
Earnings '28
x
204.47x
PE Ratio '28
=
AU$2.83b
Market Cap '28
AU$2.83b
Market Cap '28
/
127.01m
No. shares '28
=
AU$22.27
Share Price '28
AU$22.27
Share Price '28
Discounted to 2025 @ 6.48% p.a.
=
AU$18.45
Fair Value '25
